↓ Skip to main content

New advances in focal therapy for early stage prostate cancer

Overview of attention for article published in Expert Review of Anticancer Therapy, June 2017
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age and source (54th percentile)

Mentioned by

twitter
2 tweeters

Citations

dimensions_citation
11 Dimensions

Readers on

mendeley
38 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
New advances in focal therapy for early stage prostate cancer
Published in
Expert Review of Anticancer Therapy, June 2017
DOI 10.1080/14737140.2017.1345630
Pubmed ID
Authors

Kae Jack Tay, Ariel A. Schulman, Christina Sze, Efrat Tsivian, Thomas J. Polascik

Abstract

Prostate focal therapy offers men the opportunity to achieve oncological control while preserving sexual and urinary function. The prerequisites for successful focal therapy are to accurately identify, localize and completely ablate the clinically significant cancer(s) within the prostate. We aim to evaluate the evidence for current and upcoming technologies that could shape the future of prostate cancer focal therapy in the next five years. Areas Covered: Current literature on advances in patient selection using imaging, biopsy and biomarkers, ablation techniques and adjuvant treatments for focal therapy are summarized. A literature search of major databases was performed using the search terms 'focal therapy', 'focal ablation', 'partial ablation', 'targeted ablation', 'image guided therapy' and 'prostate cancer'. Expert Commentary: Advanced radiological tools such as multiparametric magnetic resonance imaging (mpMRI), multiparametric ultrasound (mpUS), prostate-specific-membrane-antigen positron emission tomography (PSMA-PET) represent a revolution in the ability to understand cancer function and biology. Advances in ablative technologies now provide a menu of modalities that can be rationalized based on lesion location, size and perhaps in the near future, pre-determined resistance to therapy. However, these need to be carefully studied to establish their safety and efficacy parameters. Adjuvant strategies to enhance focal ablation are under development.

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 38 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 38 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 7 18%
Other 6 16%
Student > Doctoral Student 4 11%
Student > Bachelor 3 8%
Student > Postgraduate 2 5%
Other 6 16%
Unknown 10 26%
Readers by discipline Count As %
Medicine and Dentistry 17 45%
Agricultural and Biological Sciences 3 8%
Economics, Econometrics and Finance 1 3%
Computer Science 1 3%
Nursing and Health Professions 1 3%
Other 2 5%
Unknown 13 34%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 August 2017.
All research outputs
#8,880,774
of 11,547,113 outputs
Outputs from Expert Review of Anticancer Therapy
#403
of 621 outputs
Outputs of similar age
#174,254
of 262,494 outputs
Outputs of similar age from Expert Review of Anticancer Therapy
#4
of 11 outputs
Altmetric has tracked 11,547,113 research outputs across all sources so far. This one is in the 19th percentile – i.e., 19% of other outputs scored the same or lower than it.
So far Altmetric has tracked 621 research outputs from this source. They receive a mean Attention Score of 3.8. This one is in the 29th percentile – i.e., 29% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 262,494 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 27th percentile – i.e., 27% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 11 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 54% of its contemporaries.